Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
112 studies found for:    "idiopathic inflammatory myopathy"
Show Display Options
RSS Create an RSS feed from your search for:
"idiopathic inflammatory myopathy"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:
2 Not yet recruiting MYOPROSP - a Prospective Cohort Study in Myositis
Conditions: Myositis;   Idiopathic Inflammatory Myopathy
Intervention:
3 Recruiting Belimumab in Myositis
Condition: Myositis
Interventions: Drug: Belimumab;   Drug: Placebo
4 Completed Arimoclomol in Sporadic Inclusion Body Myositis
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
5 Completed Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338;   Biological: Placebo
6 Completed Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)
Intervention: Drug: BYM338 (Bimagrumab)
7 Completed Lithium in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Intervention:
8 Completed Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Condition: Myositis, Inclusion Body
Intervention: Drug: Alemtuzumab (Campath)
9 Not yet recruiting Study of Arimoclomol in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
10 Completed Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention:
11 Active, not recruiting An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: Bimagrumab;   Drug: Placebo
12 Completed Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention: Drug: Etanercept
13 Recruiting Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)
Intervention: Drug: Natalizumab
14 Completed Blood-flow Restricted Exercise in Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Other: Blood-flow restricted training;   Drug: Care as usual
15 Completed Treatment With TNF Blockade, Infliximab, in Patients With Myositis
Condition: Refractory Myositis
Intervention: Drug: Infliximab
16 Completed Immune Abnormalities in Sporadic Inclusion Body Myositis
Conditions: Sporadic;   Inclusion Body;   Myositis
Intervention:
17 Recruiting Adult and Juvenile Myositis
Conditions: Dermatomyositis;   Polymyositis;   Inclusion Body Myositis
Intervention:
18 Completed Anakinra in Myositis
Conditions: Polymyositis;   Dermatomyositis;   Inclusion Body Myositis
Intervention: Drug: Anakinra
19 Active, not recruiting Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
20 Recruiting Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Condition: Inclusion Body Myositis (IBM)
Interventions: Drug: Rapamycin;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.